| Literature DB >> 23453941 |
Rafaela Gomes Ferrari1, Antonio Galiana, Rosa Cremades, Juan Carlos Rodríguez, Marciane Magnani, Maria Cristina Bronharo Tognim, Tereza C R M Oliveira, Gloria Royo.
Abstract
Several studies have been conducted in recent years to elucidate the structure, function and significance of AcrB, MarA, SoxS and RamA in Salmonella enterica. In this study, the relative quantification of acrB, soxS, marA and ramA genes expression was evaluated in 14 strains of S. enterica, with or without accompanying mutations in the quinolone resistance-determining regions of the gyrA gene, that were exposed to ciprofloxacin during the exponential growth phase. The presence of ciprofloxacin during the log phase of bacterial growth activated the genes marA, soxS, ramA and acrB in all S. enterica strains analyzed in this study. The highest expression levels for acrB were observed in strains with gyrA mutation, and marA showed the highest expression in the strains without mutation. Considering only the strains with ciprofloxacin minimum inhibitory concentration values<0.125 μg/mL (sensitive to ciprofloxacin), the most expressed gene in the strains both with and without mutations was acrB. In the strains with ciprofloxacin minimum inhibitory concentration values ≥ 0.125 μg/mL (low susceptibility), with and without mutations in gyrA, the most expressed gene was marA. In this study, we observed that strains resistant to nalidixic acid may express genes associated with the efflux pump and the expression of the AcrAB-TolC pump genes seems to occur independently of mutations in gyrA.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23453941 PMCID: PMC9427363 DOI: 10.1016/j.bjid.2012.09.011
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
TaqMan® primers and probes. Sequences of primers and probes used for qRT-PCR (quantitative real-time reverse transcriptase PCR) reactions, designed with the help of the Primer Express™ 2.0 software (Applied Biosystems).
| Primers and probes | Primers sequences 5′ → 3′ |
|---|---|
| 16s-F | CGTGTTGTGAAATGTTGGGTTAA |
| 16s-R | CCGCTGGCAACAAAGGATAA |
| probe 16s | TCCCGCAACGAGCGCAACC |
| TGAAGACCAGGGCGTATTCCT | |
| TTTTTGCGTGCGCTCTTG | |
| probe | ACAATGGTCCAGCTCCCCGCG |
| CGGAATACACGCGAGAAGGT | |
| GAGCGCCCGATTTTTGATATC | |
| probe soxS | TGCTGCGATACATAGCCCAGGTCCA |
| GACCCGGACGTTCAAAAACTAT | |
| TCGCCATGCATATTGGTGAT | |
| probe | TGATGTGCCGCCACACAAATACCG |
| CCAGAAGGTGTATGATATTTGTCTCAAG | |
| GGTTGAACGTGCGGGTAAA | |
| probe | TTGATTCGCAGCAAACCTTTACGCG |
Probe used: 6-carboxyfluorescein (FAM); quencher used: 6-carboxytetramethylrhodamine (TAMRA).
Fig. 1Distribution of the expression levels of the marA, soxS, ramA and acrB genes studied in relation to CipMIC (μg/mL) and gyrA gene mutations. WT, wild-type strain; CIP, ciprofloxacin.
Distribution of the mutations observed in QRDR of the gyrA gene in Salmonella strains of different serovars with the corresponding minimal inhibitory concentration for ciprofloxacin (CipMIC) and geometric mean (GM) data.
| Strain | Serotype | CipMIC (μg/mL) | Mutation | Level of expression in the presence of ciprofloxacin | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| d | d | d | d | GM | ||||||||
| 250-2 | Enteriditis | 0.0156 | Ser83-Tyr | 1.39 | 0.11 | 7.26 | 0.51 | 7.67 | 0.38 | 2.46 | 0.26 | 3.71 |
| 229-2 | Enteriditis | 0.0156 | Asp87-Asn | 1.88 | 0.14 | 2.60 | 0.47 | 4.70 | 0.07 | 19.43 | 0.78 | 4.60 |
| 213-2 | Enteriditis | 0.0156 | Asp87-Asn | 0.40 | 0.30 | 2.26 | 0.20 | 22.16 | 0.16 | 9.78 | 0.33 | 3.74 |
| 209-2 | Enteriditis | 0.1250 | Ser83-Tyr | 9.65 | 0.13 | 11.96 | 0.30 | 37.27 | 0.54 | 0.30 | 0.85 | 5.99 |
| 300-2 | Enteriditis | 0.2500 | Ser83-Phe | 1.99 | 0.61 | 3.16 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 |
| 288-2 | Heidelberg | 0.5000 | Ser83-Tyr | 2.71 | 0.46 | 0.98 | 1.30 | 0.59 | 0.79 | 0.00 | 0.00 | 0.63 |
| 216-2 | Enteriditis | 0.5000 | Ser83-Tyr | 1.00 | 0.11 | 3.43 | 0.16 | 2.20 | 0.27 | 1.01 | 0.70 | 1.66 |
| 238-2 | Enteriditis | 0.2500 | wt | 42.2 | 0.29 | 9.65 | 0.40 | 3.43 | 0.22 | 38.85 | 0.19 | 15.26 |
| 121-1 | Enteriditis | 0.3800 | wt | 4.66 | 0.31 | 2.82 | 0.72 | 7.89 | 0.40 | 5.74 | 0.46 | 4.94 |
| 135-2 | Enteriditis | 0.3800 | wt | 2.90 | 0.45 | 122 | 0.20 | 9.19 | 0.24 | 0.00 | 0.00 | 4.25 |
| 91-1 | Enteriditis | 0.1250 | wt | 6.96 | 0.96 | 8.50 | 0.43 | 1.56 | 0.14 | 8.22 | 0.43 | 5.25 |
| 119-2 | Enteriditis | 0.0470 | wt | 2.27 | 0.18 | 9.19 | 0.38 | 11.80 | 0.36 | 1.25 | 0.30 | 4.19 |
| 232-2 | Enteriditis | 0.5000 | wt | 0.16 | 0.68 | 1.29 | 0.39 | 0.00 | 0.00 | 0.13 | 1.25 | 0.23 |
| 297-2 | Corvallis | 0.5000 | wt | 0.79 | 0.33 | 2.31 | 0.13 | 0.97 | 0.19 | 0.00 | 0.00 | 0.65 |
wt, strain without mutations in gyrA, gyrB, parC and parE.
All strains were resistant to NAL.
Typical deviation.
Geometric mean of the four genes.
Strain positive for qnrB19.